Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 29, 2013

Idera, NCI to Pit TLR Antagonists against B-Cell Lymphomas

  • Idera Pharmaceuticals entered into a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Cancer Institute (NCI) to evaluate the company’s Toll-like receptor (TLR) antagonists as a potential approach to the treatment of certain genetically defined B-cell lymphomas.

    Idera's technology platform, according to the firm, involves creating synthetic RNA- and DNA-based compounds to modulate immune responses. Idera has applied this platform to develop TLR antagonists as immunomodulatory drug candidates.

    Recently, Idera presented results of a Phase I trial of IMO-8400, an antagonist of TLRs 7, 8, and 9 being developed for potential applications in autoimmune and inflammatory diseases. In addition to being well tolerated at all dose levels, IMO-8400-treated subjects showed inhibition of TLR 7-, 8-, and 9-mediated cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interferon-alpha (IFN-α), and other pro-inflammatory cytokines. Another TLR antagonist, IMO-3100, is currently being tested in patients with moderate to severe plaque psoriasis.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »